Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: Examining confounding and misclassification biasin cancer observational comparative effectiveness research

Value in Health

Volumn 16, Issue 4, 2013, Pages 610-618

  Bekelman, Justin E ^a,b   Handorf, Elizabeth A ^c   Guzzo, Thomas ^a   Evan Pollack, Craig ^d   Christodouleas, John ^a   Resnick, Matthew J ^e   Swisher Mcclure, Samuel ^a   Vaughn, David ^a   Ten Have, Thomas ^a   Polsky, Daniel ^a,b   Mitra, Nandita ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

chemotherapy; comparative effectiveness research; cystectomy; radiotherapy; SEER Program; urinary bladder neoplasms

Indexed keywords

AGED; ARTICLE; BLADDER PRESERVING THERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; COMPARATIVE EFFECTIVENESS RESEARCH; COMPUTER SIMULATION; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYSTECTOMY; FEMALE; HUMANS; MALE; MEDICARE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84879411317     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.01.005     Document Type: Article

References (23)

1. J. Efstathiou, D.Y. Spiegel, and W.U. Shipley Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience Eur Urol 61 2012 705 711
2. N.D. James, S.A. Hussain, and E. Hall Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer N Engl J Med 366 2012 1477 1488
3. R.S. Svatek, S.F. Shariat, and G. Novara Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort BJU Int 107 6 2011 898 904
4. J.L. Gore, M.S. Litwin, and J. Lai Use of radical cystectomy for patients with invasive bladder cancer J Natl Cancer Inst 102 2010 802 811
5. D. Schrag, N. Mitra, and F. Xu Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population Urology 65 2005 1118 1125
6. B.K. Hollenbeck, Y. Wei, and J.D. Birkmeyer Volume, process of care, and operative mortality for cystectomy for bladder cancer Urology 69 2007 871 875
7. A. Elixhauser, C. Steiner, D. Harris, and R. Coffey Comorbidity measures for use with administrative data Med Care 36 1998 8 27
8. D. Homer, and S. Lemeshaw Applied Survival Analysis: Regression Modeling of Time to Event Data 1999 John Wiley and Sons New York
9. D.B. Rubin, and N. Thomas Matching using estimated propensity scores: relating theory to practice Biometrics 52 1996 249 264
10. L.H. Curtis, B.G. Hammill, and E.L. Eisenstein Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases Med Care 45 10, Suppl. 2 2007 S103 S107
11. D.Y. Lin, and L.J. Wei The robust inference for the proportional hazards model J Am Stat Assoc 84 1989 1074 1078
12. P. Rosenbaum, and D. Robin Reducing bias in observational studies using subclassification on the propensity score J Am Stat Assoc 79 1984 516 524
13. D. Collett Modelling Survival Data in Medical Research 2nd ed. 2003 Chapman and Hall/CRC New York, NY
14. L. Wei The accelerated failure time model: a useful alternative to the Cox regression in survival analysis Stat Med 11 1992 1871 1879
15. M.A. Brookhart, J.A. Rassen, and S. Schneeweiss Instrumental variable methods in comparative safety and effectiveness research Pharmacoepidemiol Drug Saf 19 2010 537 554
16. J.V. Terza, A. Basu, and P.J. Rathouz Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling J Health Econ 27 2008 531 543
17. B. Efron, and R.J. Tibshirani An Introduction to the Bootstrap 1994 Chapman & Hall Boca Raton, FL
18. G. Simone, and M. Gallucci Multimodality treatment versus radical cystectomy: bladder sparing at cost of life? Eur Urol 61 2012 712 714
19. D.S. Kaufman, W.U. Shipley, and A.S. Feldman Bladder cancer Lancet 374 2009 239 249
20. K.M. Harris, and D.K. Remler Who is the marginal patient? Understanding instrumental variables estimates of treatment effects Health Serv Res 33 5, Pt 1 1998 1337 1360
21. B.M. Stiles, E.L. Servais, and P.C. Lee Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging J Thorac Cardiovasc Surg 137 2009 13 19
22. Cooke E.W., Shrieve D.C., Tward J.D. Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate? 2012;35:364-8.
23. D.A. Chokshi, J. Avorn, and A.S. Kesselheim Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature Health Aff (Millwood) 29 2010 1842 1848